EMILY ELSWICK: Open Payments
NPI 1568910461 · LA FAYETTE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,267 in 70 payments from 17 companies in 2025. Trend: 2023 $1,374 · 2024 $848 · 2025 $1,267
Food & beverage: $1,267
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $280 |
| Lilly USA, LLC | 11 | $156 |
| Novo Nordisk Inc | 9 | $148 |
| Otsuka America Pharmaceutical, Inc. | 6 | $122 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $81 |
| PFIZER INC. | 4 | $80 |
| Lundbeck LLC | 3 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $52 |
Products named: REXULTI, VRAYLAR, Ozempic, XIFAXAN, JARDIANCE, MOUNJARO, QULIPTA, GEMTESA.
Industry payments across GA — which companies pay providers there.
